Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00060489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00060489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2002
Completion date
September 30, 2003
Enrollment
Not reported
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar disorder, depression, bipolar